PDF(Pubmed)
Abstract：
UNASSIGNED: Negative symptoms are part of the clinical manifestations of schizophrenia and their presence is associated with a poorer prognosis, significantly limited vocational opportunities, impaired quality of life and social functioning. In the clinical practice, treatment of negative symptoms in patients with schizophrenia, is a challenge. Cariprazine is a novel partial agonist of D3 and D2 receptors, and shows a high affinity for D3, with good tolerability, good response to schizophrenic symptoms and limited side effects. We present two cases of young patients with predominantly negative symptoms during treatment with an atypical antipsychotic, administered in a stable dose and therapeutic range, and for at least 4 weeks prior to the Cariprazine switch.
UNASSIGNED: Two patients (men aged 21 and 22) with schizophrenia, exhibiting predominantly negative symptoms, are presented. Their diagnosis was based on, DSM-5 criteria (295.10).Patients were treated with Cariprazine at a daily dose of 4.5 mg. They were followed for a period of 18 months and assessed with Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF) and Clinical Global Impression-Severity (CGI-S), at the fourth week of initiation of treatment with Cariprazine, at 6 months, at 12 months and at 18 months. Their mean initial value was 75.5 on PANSS, 4.0 on CGI-S, and 52.5 on GAF. Both patients were treated with stable doses of atypical antipsychotic-Risperidone at a daily dose of 4,5 mg. Cross-titration to Cariprazine was initiated, from 1.5 mg daily dose up to 4,5 mg daily dose, during a period of 2 weeks.
UNASSIGNED: After 18 months of treatment with Cariprazine at a daily dose of 4.5 mg, the following results were reported: mean value was 57.5 on PANSS, 3.0 on CGI-S, and 74.5 on GAF. The overall PANSS mean score decreased by 23.8%, the CGI-S mean score improved by 25% and the mean GAF score increased by 29.5%. The positive PANSS subscale score decreased minimally, from 20 to 16, while for the negative subscale the improvement was 29.8%.Cariprazine was well tolerated by patients and no side effects were observed from it during therapy.
UNASSIGNED: After 18 months Cariprazine succeeded in improving negative symptoms, global functioning, and global clinical impression. In young schizophrenic patients with a predominance of negative symptoms, the cariprazine may be a successful alternative.
UNASSIGNED: Two patients (men aged 21 and 22) with schizophrenia, exhibiting predominantly negative symptoms, are presented. Their diagnosis was based on, DSM-5 criteria (295.10).Patients were treated with Cariprazine at a daily dose of 4.5 mg. They were followed for a period of 18 months and assessed with Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF) and Clinical Global Impression-Severity (CGI-S), at the fourth week of initiation of treatment with Cariprazine, at 6 months, at 12 months and at 18 months. Their mean initial value was 75.5 on PANSS, 4.0 on CGI-S, and 52.5 on GAF. Both patients were treated with stable doses of atypical antipsychotic-Risperidone at a daily dose of 4,5 mg. Cross-titration to Cariprazine was initiated, from 1.5 mg daily dose up to 4,5 mg daily dose, during a period of 2 weeks.
UNASSIGNED: After 18 months of treatment with Cariprazine at a daily dose of 4.5 mg, the following results were reported: mean value was 57.5 on PANSS, 3.0 on CGI-S, and 74.5 on GAF. The overall PANSS mean score decreased by 23.8%, the CGI-S mean score improved by 25% and the mean GAF score increased by 29.5%. The positive PANSS subscale score decreased minimally, from 20 to 16, while for the negative subscale the improvement was 29.8%.Cariprazine was well tolerated by patients and no side effects were observed from it during therapy.
UNASSIGNED: After 18 months Cariprazine succeeded in improving negative symptoms, global functioning, and global clinical impression. In young schizophrenic patients with a predominance of negative symptoms, the cariprazine may be a successful alternative.
摘要：
■阴性症状是精神分裂症临床表现的一部分，它们的存在与预后较差有关，职业机会非常有限，生活质量和社会功能受损。在临床实践中,治疗精神分裂症患者的阴性症状，是一个挑战。Cariprazine是一种新型的D3和D2受体部分激动剂，并显示出对D3的高亲和力，具有良好的耐受性，对精神分裂症症状反应良好，副作用有限。我们介绍了两例在使用非典型抗精神病药物治疗期间以阴性症状为主的年轻患者，以稳定的剂量和治疗范围施用，和至少4周之前，卡里吡嗪转换。
■两名精神分裂症患者（21岁和22岁的男性），主要表现为阴性症状，被呈现。他们的诊断是基于，DSM-5标准(295.10)。患者以4.5mg的日剂量接受卡利哌嗪治疗。随访18个月，用阳性和阴性综合征量表(PANSS)评定，全球功能评估（GAF）和临床全球印象严重程度（CGI-S），在开始卡利拉嗪治疗的第四周，6个月时,在12个月和18个月。它们在PANSS上的平均初始值为75.5，CGI-S上的4.0，和GAF上的52.5。两名患者均接受稳定剂量的非典型抗精神病药-利培酮治疗，每日剂量为4.5mg。开始对Cariprazine进行交叉滴定，从1.5毫克每日剂量到4,5毫克每日剂量，在2周的时间内。
■用4.5mg日剂量的卡瑞哌嗪治疗18个月后，报告了以下结果：PANSS的平均值为57.5，CGI-S上的3.0，和GAF上的74.5。总体PANSS平均得分下降了23.8%，CGI-S平均评分提高了25%,GAF平均评分提高了29.5%.阳性PANSS分量表评分下降幅度最小，从20到16，而对于负分量表，改善为29.8%。患者对Cariprazine的耐受性良好，治疗期间未观察到任何副作用。
18个月后，Cariprazine成功改善了阴性症状，全球运作，和全球临床印象。在以阴性症状为主的年轻精神分裂症患者中，卡利拉嗪可能是一个成功的替代品。
■两名精神分裂症患者（21岁和22岁的男性），主要表现为阴性症状，被呈现。他们的诊断是基于，DSM-5标准(295.10)。患者以4.5mg的日剂量接受卡利哌嗪治疗。随访18个月，用阳性和阴性综合征量表(PANSS)评定，全球功能评估（GAF）和临床全球印象严重程度（CGI-S），在开始卡利拉嗪治疗的第四周，6个月时,在12个月和18个月。它们在PANSS上的平均初始值为75.5，CGI-S上的4.0，和GAF上的52.5。两名患者均接受稳定剂量的非典型抗精神病药-利培酮治疗，每日剂量为4.5mg。开始对Cariprazine进行交叉滴定，从1.5毫克每日剂量到4,5毫克每日剂量，在2周的时间内。
■用4.5mg日剂量的卡瑞哌嗪治疗18个月后，报告了以下结果：PANSS的平均值为57.5，CGI-S上的3.0，和GAF上的74.5。总体PANSS平均得分下降了23.8%，CGI-S平均评分提高了25%,GAF平均评分提高了29.5%.阳性PANSS分量表评分下降幅度最小，从20到16，而对于负分量表，改善为29.8%。患者对Cariprazine的耐受性良好，治疗期间未观察到任何副作用。
18个月后，Cariprazine成功改善了阴性症状，全球运作，和全球临床印象。在以阴性症状为主的年轻精神分裂症患者中，卡利拉嗪可能是一个成功的替代品。
